Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
115 results about "Anti her2" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The Anti-HER2 isotype family features the variable region of trastuzumab.Trastuzumab is a humanized IgG1 monoclonal antibody that targets the HER2 receptor (also known as HER2/neu) that is found on the cell membrane of epithelial cells. HER2 plays an important role in normal cell growth and differentiation.
Multifactorial assay for cancer detection
InactiveUS20050069963A1Rapid and early detectionPeptide/protein ingredientsMicrobiological testing/measurementAnti her2Anti-MUC-1
Provided are methods for the rapid detection of ovarian cancer. The methods employ a multiplex immunoassay to detect levels of two or more of the markers EGF, G-CSF, IL-6, IL-8, CA-125, VEGF, MCP-1, anti-IL6, anti-IL8, anti CA-125, anti-c-myc, anti-p53, anti-CEA, anti-CA 15-3, anti-MUC-1, anti-survivin, anti-bHCG, anti-osteopontin, anti-PDGF, anti-Her2 / neu, anti-Akt1, anti-cytokeratin 19, cytokeratin 19, EGFR, CEA, kallikrein-8, M-CSF, FasL, ErbB2 and Her2 / neu in a sample of the patient's blood, where the presence of abnormal levels of two or more of the markers indicates the presence of ovarian cancer in the patient. An array also is provided to quantitate levels of these markers in a patient's blood. Also provided is a method of predicting onset of clinical ovarian cancer comprising determining the change in concentration over time of two or more of anti-Her2 / neu, anti-MUC-1, anti-c-myc, anti-p53, anti-CA-125, anti-CEA, anti-CA 72-4, anti-PDGFRα, IFNγ, IL-6, IL-10, TNFα, MIP-1α, MIP-1β, EGFR and Her2 / neu in a patient's blood.
Owner:UNIVERSITY OF PITTSBURGH
Tumor therapy with an Anti-vegf antibody
InactiveUS20100285010A1Prevents and reduces metastasisImmunoglobulins against growth factorsAntibody ingredientsAfter treatmentAnti vegf antibody
Owner:FRIESS THOMAS +2
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
InactiveUS7306801B2Promotes therapeutic responseImproved therapeutic responsePowder deliveryPeptide/protein ingredientsDosing regimenAnti her2
Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered as two separate pharmaceutical compositions, one containing IL-2 (or variant thereof), the other containing at least one anti-HER2 antibody (or fragment thereof), according to a dosing regimen. Administering of these two agents together potentiates the effectiveness of the anti-HER2 antibody alone, resulting in a positive therapeutic response that is improved with respect to that observed with this anti-tumor agent.
Owner:HEALTH RES INC +1
Method for purifying anti-HER2 or/and anti-HER3 antibody proteins
ActiveCN102492040ASpeed up filteringReduce manufacturing costImmunoglobulins against cell receptors/antigens/surface-determinantsPeptide preparation methodsVirus inactivationPurification methods
The invention belongs to the biochemistry technical field, concretely relates to a method for purifying anti-HER2 or / and anti-HER3 antibody proteins. The method of the invention comprises the following the steps: clarifying a broth, carrying out affinity chromatography, carrying out inactivation on virus by acidic pH value, carrying out cation exchange chromatography, carrying out anion exchange chromatography; and filtering virus; wherein, the step of virus inactivation by acidic pH value and the step of virus filtration can be inserted at any position of the step after the affinity chromatography. The method of the invention comprises the following advantages that: 1) the chromatography step can be reduced to three steps, thereby the production efficiency can be enhanced and the production cost can be minimized. 2) the step of virus filtration is added, thereby the security can be raised.
Owner:GENOR BIOPHARMA +1
Therapeutic Anti-her2 antibody fusion polypeptides
InactiveUS20090226466A1Enhanced cell killing of cellImprove efficiencySugar derivativesAntibody mimetics/scaffoldsTherapeutic proteinAnti her2
Therapeutic protein fusions comprising anti-HER2 antibody and MicB sequences are described along with methods for their production and use
Owner:GENENTECH INC
MicroRNA Signatures Predicting Responsiveness To Anti-HER2 Therapy
InactiveUS20130065778A1Reduce expressionHigh expressionNucleotide librariesMicrobiological testing/measurementMedicineAnti her2
The invention provides miRNA signatures and methods of making and using thereof. MiRNA signatures determine the responsiveness of HER2 expressing breast tumors to anti-HER2 treatment, such as the targeted drug therapy trastuzumab.
Owner:YALE UNIV
Combination Therapy Using Anti-EGFR and Anti-HER2 Antibodies
InactiveUS20090214541A1Good curative effectPrevent dimerizationAntibody ingredientsImmunoglobulinsEGFR AntibodyAnti her2
The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Anti-HER2 antibodies and compositions
The present invention relates to novel therapeutic antibodies directed against HER2 (ErbB2), as well as recombinant polyclonal anti-HER2 antibody compositions comprising at least two of said recombinant anti-HER2 antibodies, and use of the antibodies and antibody compositions for treatment of cancer.
Owner:SYMPHOGEN AS
Antibody composition preparation and application thereof
ActiveCN102961745AAvoid formingAvoid gatheringAntibody ingredientsAntineoplastic agentsAnti her2Pertuzumab
Relating to the technical field of pharmaceutical preparations, the invention provides an antibody composition preparation composed of Trastuzumab and Pertuzumab. The antibody composition preparation has better tumor treatment activity. Compared with the independent treatment of Trastuzumab and Pertuzumab, the composition preparation shows a synergistic effect of the two antibodies, and can reach a tumor control rate of 92.43%. And the preparation provided in the invention has better stability, thus being in favor of long-term preservation of the antibody composition preparation. The antibody composition preparation provided in the invention is applicable to preparation of drugs treating diseases or symptoms suited to anti-HER2 antibody therapy. During application, the antibody composition preparation disclosed in the invention is used with a chemotherapeutic agent jointly or sequentially.
Owner:SUZHOU KANGJU BIOTECHNOLOGY CO LTD +1
Anti-HER2 antibodies and immunoconjugates
Owner:GENENTECH INC
HER2-resistant humanized antibody and relevant tumor-resistant composition thereof
ActiveCN104225594AHybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsHeavy chainAnti her2
The invention discloses an HER2-resistant humanized antibody and a relevant tumor-resistant composition thereof. The HER2-resistant humanized antibody in the tumor resistant composition provided by the invention is an HER2-resistant humanized antibody M1 containing a humanized heavy chain variable region M1-VH and a humanized light chain variable region M1-VL which both consist of a determinant complementary region and a framework region, the determinant complementary regions of the M1-VH and the M1-VL both consist of CDR1, CDR2 and CDR3; the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the M1-VH are respectively shown as the 26th to 35th, the 50th to 66th, and the 99th to 109th of the SEQID No.1; the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the M1-VL are respectively shown as the 24th to 40th, the 56th to 62th, and the 95th to 103th of the SEQID No.2.
Owner:HEFEI HANKEMAB BIOTECH CO LTD
Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
Owner:GENENTECH INC
Stable anti-HER2 humanized antibody preparation
The invention discloses a humanized anti-HER2 antibody preparation, which contains humanized anti-HER2 antibody, protective agent, buffering agent, surfactant and isotonic regulator. The invention has the advantages of stability and low price.
Owner:SHANGHAI NAT ENG RES CENT OF ANTIBODY MEDICINE
Fully humanized anti-HER2 antibody, preparation method and use thereof
ActiveUS8974785B2High affinityEnhanced inhibitory effectAnimal cellsSugar derivativesHeavy chainNucleotide
The invention provides a fully human anti-HER2 monoclonal antibody, which has an amino acid sequence of heavy chain variable region as shown in SEQ ID NO: 6 and an amino acid sequence of light chain variable region as shown in SEQ ID NO: 8. The invention also discloses the nucleotide sequence encoding the antibody, the expression vector and the host cell comprising the nucleotide sequence, and the use of the antibody for manufacturing the medicament for the treatment of tumor.
Owner:YUEHAI BIOPHARM SHAOXING LTD
Human monoclonal antibody of human endophloeodal growth factor receptor 2 protein and its preparing process
InactiveCN1396182ASolve the HAMA problemGood treatment effectImmunoglobulins against growth factorsFermentationTreatment effectAnti her2
A humanized monoclonal antibody of human endophloeodal growth factor receptor 2 protein is prepared from enternal segment of HER2 / neucell through such steps as culturing the B cells of the person sensitive to HER2; fusing the said B cells with human osteoma cells (karpas 707 H); screening the external segment monoclonal anti body against HER2 cell; and amplification of the said monoclonal antibody. It features that antigen epitope is the external segment polypeptide of HER2 / neu cell for specifically binding the external segment of HER2 / neu cell, and the all gene sequences for syntehsis come from human B lymph cells and human osteoma cells.
Owner:陕西超英生物医学研究开发有限公司
Anti-HER2 chimeric antigen receptor, encoding gene, recombinant expression vector, construction method of recombinant expression vector, and application
ActiveCN105949318AImprove in vitro killing effectGood clinical effectPeptide/protein ingredientsMammal material medical ingredientsSingle-Chain AntibodiesAntigen receptors
The invention discloses an anti-HER2 chimeric antigen receptor, an encoding gene, a recombinant expression vector, a construction method of the recombinant expression vector, and an application. The anti-HER2 chimeric antigen receptor comprises CD8 leader chimeric receptor signal peptide, an HER2 single-chain antibody heavy chain VH, Optimal Linker C, an HER2 single-chain antibody light chain VL, a CD8 Hinge chimeric receptor hinge, a CD8 Transmembrane chimeric receptor transmembrane domain, a CD137 chimeric receptor co-stimulated factor and a TCR chimeric receptor T cell activating domain which are connected in series. Moreover, the invention discloses an encoding gene of the anti-HER2 chimeric antigen receptor, a recombinant expression vector, a construction method of the recombinant expression vector, and an application. Secretion of cell factors and an in-vitro killing effect of CAR-T cells are obviously improved, and the CAR-T cells have an outstanding clinical treatment effect.
Owner:SHANGHAI UNICAR THERAPY BIOPHARM TECH CO LTD
Bispecific Anti-her2 antibody
The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.
Owner:BEIJING MABWORKS BIOTECH
Targeting trastuzumab-resistant her2+ breast cancer with a her3-targeting nanoparticle
InactiveUS20160060316A1Organic active ingredientsFusion with DNA-binding domainTherapy resistantAnti her2
Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.Further disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to anti-HER2 therapy; and administering to the patient a therapeutically effective amount of a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence. Finally disclosed herein are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence
Owner:CEDARS SINAI MEDICAL CENT
Anti-HER2 glycoantibodies and uses thereof
ActiveUS10005847B2Increase healing valueHigh activityOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsFc(alpha) receptorFc receptor
Owner:ACAD SINIC
Anti-HER2 antibodies and compositions
InactiveCN102884084AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCross-linkTherapeutic antibody
The present invention relates to novel therapeutic antibodies directed against HER2 (ErbB2), as well as recombinant polyclonal anti-HER2 antibody compositions, and use of the antibodies and antibody composition for treatment of cancers. The antibody composition comprises at least three recombinant antibodies that bind distinct epitopes of HER2. Two of the antibodies bind to HER2 on the surface of a cell such that they generate a cross-linked antibody-receptor lattice on the cell surface and thereby result in HER2 receptor internalization. The third antibody in the composition binds HER2 such that it blocks heterodimerization between HER2 and HER3.
Owner:SYMPHOGEN AS
Fully humanized Anti-her2 antibody, preparation method and use thereof
ActiveUS20120309942A1Antibody affinity is highEnhanced inhibitory effectAnimal cellsSugar derivativesHeavy chainNucleotide
The invention provides a fully human anti-HER2 monoclonal antibody, which has an amino acid sequence of heavy chain variable region as shown in SEQ ID NO: 6 and an amino acid sequence of light chain variable region as shown in SEQ ID NO: 8. The invention also discloses the nucleotide sequence encoding the antibody, the expression vector and the host cell comprising the nucleotide sequence, and the use of the antibody for manufacturing the medicament for the treatment of tumor.
Owner:YUEHAI BIOPHARM SHAOXING LTD
CAR-T cell as well as preparation method and application thereof
InactiveCN106047817APromote secretionEnhance the effect of killing tumor cellsAntibody mimetics/scaffoldsNGF/TNF-superfamilyAntigenCell membrane
Owner:SHEN ZHEN ISTEM REGENERATIVE MEDICINE SCI TECH CO LTD
Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
ActiveCN102036660AImprove anti-tumor activityCompound screeningOrganic active ingredientsMetaboliteAnti her2
Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Owner:GENENTECH INC
Preparation method of human T cell carrying anti-Her2/CD3 bispecific function protein
ActiveCN104829729AImprove targetingImprove bindingHybrid immunoglobulinsGenetic material ingredientsT-Cell SpecificityBispecific antibody
The invention relates to the biotechnical field, and especially relates to a bispecific antibody. The bispecific antibody comprises a first antibody segment and a second antibody segment, the first antibody segment is an antitumor antigen-antibody segment, and the second antibody segment is an anti-human CD3 molecule antibody segment. A bispecific antibody principle is used to construct the Her2 tumor antigen and T cell specific bispecific antibody, and adoptively transferred T cells are used to carry and continuously express the antibody protein in vivo, so the bispecific antibody has an in vivo killing effect, generates enough T effect effects, and optimizes the effect performance efficiency.
Owner:FUDAN UNIV
Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle
InactiveUS9850293B2Organic active ingredientsFusion with DNA-binding domainTherapy resistantAnti her2
Owner:CEDARS SINAI MEDICAL CENT
Active segment of HER2/neu with Herstatin interaction, coding gene and application thereof
An active fragment for the mutual action between HER2 / neu and Herstation is the polypeptide with the amino acid residue sequence shown by SEQ ID No.1 or the polypeptide whose amino acid residue sequence has one or more substituted or lost, or added residues. It is also a sensitive site, where HER2 / neu molecule can be effectively suppressed. It can play its role in preparing the HER2 / neu antagonistic medicines.
Owner:INST OF BASIC MEDICAL SCI ACAD OF MILITARY MEDICAL SCI OF PLA
Novel bifunctional antibody conjugate, preparation method and application thereof
The invention provides a novel bifunctional antibody conjugate, a preparation method and application thereof. The bifunctional antibody conjugate provided by the invention includes the structure of: a first antibody specifically directed at immune cells and a second antibody specifically directed at tumor markers, with the two antibodies coupled together through a coupling arm. The bifunctional antibody conjugate can significantly improve the tumor-killing activity after combination with an immune cell (like CIK). The invention also provides application of the novel bifunctional antibody conjugate in treatment of tumors and other diseases. The invention also provides an anti-HER2 positive cancer bispecific antibody and a preparation process. According to the invention, the bispecific antibody with high coupling rate and high activity can be simply and quickly produced, and the CIK tumor-killing activity can be improved by 2-6 times.
Owner:SHANGHAI YUYAN BIOTECH CO LTD
Anti-Her2/PD-1 bispecific antibody and preparation method thereof
InactiveCN109021110AReduce formationHybrid immunoglobulinsAntibody ingredientsMedicineBispecific antibody
The invention discloses an anti-Her2 / PD-1 bispecific antibody and a preparation method thereof, and belongs to the field of biotechnology. The anti-Her2 / PD-1 bispecific antibody can bind to Her2 and bind to PD-1, and can effectively enhance immune response by blocking a Her2 and / or PD-1 signaling pathway, so that the anti-Her2 / PD-1 bispecific antibody is possible to have a good effect of enhancingthe anti-tumor immune response.
Owner:苏州塞恩塔生物技术有限公司
Anti-HER2 polyclonal antibody as well as preparation method and application thereof
InactiveCN103910800AStrong specificityHigh sensitivityEgg immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsHer2 expressionAnti her2
The invention provides an anti-HER2 polyclonal antibody as well as a preparation method and application thereof, wherein the anti-HER2 polyclonal antibody is applied in preparation of an immune detection tool for detecting HER2 protein. The anti-HER2 polyclonal antibody is applied in preparation of a kit used for diagnosing malignancy generated by excessive HER2 expression. The anti-HER2 polyclonal antibody provided by the invention is used for providing a high-specificity, high-sensitivity and high-quality antibody for HER2 protein antigen detection.
Owner:杭州雅盛生物科技有限公司
Fucose-removed anti-HER2 antibody and application thereof
InactiveCN106543286AGrowth inhibitionSuppress generationAntibody ingredientsImmunoglobulinsAnti her2BULK ACTIVE INGREDIENT
The invention provides a fucose-removed anti-HER2 antibody which is produced by cells with the FUT8 gene knocked out. The amino acid sequence of the fucose-removed anti-HER2 antibody is shown as SEQ ID NO: 1, and the nucleotide sequence is shown as SEQ ID NO: 2. Furthermore, the antibody comprises a CH2 structural domain; the amount of fucose in the CH2 structural domain is zero. The invention further provides a medicine with the fucose-removed anti-HER2 antibody serving as an active ingredient, and a reagent, a composition or a kit with the fucose-removed anti-HER2 antibody serving as an active ingredient. Compared with a fucose-containing anti-HER2 antibody, the antibody disclosed by the invention is higher in activity, and shows good tumor inhibition activity in both expression and low expression of herceptin-resistant HER2.
Owner:BIORAY LABORATORIES INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com